inv-29: Age / life expectancy limitation — routine screening >=75 not medically necessary unless life expectancy >=10 years

Age / life expectancy limitation: Routine screening in members 75 years or older is not medically necessary unless life expectancy is greater than or equal to 10 years.

• Provider action: Document life expectancy assessment and rationale when ordering screening in patients >=75.

Use specified CPT/HCPCS and PSA assay codes for covered screening

When submitting claims for covered screening services, use the listed CPT/HCPCS and PSA assay codes (e.g., G0102 for DRE; G0103 for PSA; 84152–84154 for PSA assays) when the member meets the policy selection criteria.

• G0102 — Prostate cancer screening; digital rectal examination
• G0103 — Prostate cancer screening; prostate specific antigen test (PSA)
• 84152, 84153, 84154 — PSA assay codes (complexed, total, free)

Non‑PSA blood tests (investigational) — documentation/prior‑auth guidance

Novel non-PSA blood tests (for example, Apifiny) are considered investigational and are not FDA approved; providers offering such tests should document investigational status and provide clinical justification if submitted for coverage consideration.

• Apifiny measures eight prostate-cancer–specific autoantibodies and is not FDA approved.
• NCCN Biomarkers Compendium does not list Apifiny.

Prior authorization not specified for MRI/biopsy pathway

The policy text describes diagnostic pathways (PSA → MRI → biopsy) but does not specify payer prior authorization requirements for these steps in the cited sections.

No prior authorization specified in Additional Information

No prior authorization requirements are specified in the additional information section of the policy.

Consider novel biomarkers only after standard evaluation

Use novel biomarkers only after standard evaluation (PSA/DRE) and when results would be expected to change management, given limited evidence and concerns about over-diagnosis.

• Standard PSA/DRE screening remains the common approach; many novel biomarkers lack consistent validation.
• Consider novel tests only if they would alter clinical management after established evaluation.

Sequential PSA → MRI → targeted biopsy pathway used in trials

Clinical trials described a sequential diagnostic pathway: initial PSA screening with referral for MRI if PSA is elevated (e.g., ≥3 ng/mL), followed by targeted biopsy (with or without systematic biopsy depending on trial arm).

• STHLM3-MRI and GOTEBORG-2 trials used PSA ≥3 ng/mL as a threshold to refer for MRI.
• Trials randomized men to MRI-targeted strategies (targeted-only or targeted+systematic) versus standard biopsy.

Shared decision‑making required for screening requests

Providers should engage in shared decision-making and provide objective information about potential benefits and harms of prostate cancer screening to patients who request screening.

• Discuss benefits, limitations, and uncertainties of early detection and treatment.
• Clinician discretion in decision to perform routine PSA/DRE screening is emphasized.

Required clinical documentation for screening interpretation

Maintain clinical documentation that supports interpretation of screening and biopsy decisions, including PSA values, DRE findings, biopsy outcomes (benign, indolent, clinically significant), and ancillary test results (e.g., PSA velocity, PSA fractions) when relevant.

• Record PSA and DRE results and any prior elevated PSAs or symptoms prompting testing.
• Document biopsy classification and any ancillary biomarker results used to guide decisions.

Safety triggers for negative MRI (Stockholm3 ≥25%)

As a safety mechanism used in the STHLM3‑MRI trial, men with negative MRI but Stockholm3 scores ≥25% were recommended to undergo standard biopsy; alternative safety triggers in practice could include high PSA (e.g., ≥10 ng/mL), low free PSA, or elevated PSA density.

• Stockholm3 score ≥25% prompted standard biopsy despite negative MRI in the trial.
• Other safety criteria mentioned include PSA ≥10 ng/mL, free PSA, and PSA density.

Refer to Aetna resources and notices for plan‑specific details

See Aetna resources (Glossary, Program Provisions, Plan Disclosures) and Clinical Policy Bulletin notes for additional information; the policy contains legal and administrative disclaimers about coverage and plan-specific provisions.

• Additional links and notices are provided in the Additional Information section.
• Clinical Policy Bulletins are not offers of coverage and may be updated.

Screening may increase detection and over‑diagnosis without short‑term mortality benefit

Randomized trial evidence cited shows screening increases cancer detection without reducing short‑term mortality and can lead to substantial over‑diagnosis and over‑treatment; providers should consider these outcomes when recommending screening.

• Large RCT (n=76,693) found higher incidence with screening but no reduction in deaths at 7 years.
• Many men with low‑risk tumors subsequently receive aggressive treatment.

MRI plus targeted biopsy reduces unnecessary biopsies and over‑diagnosis

Trials indicate MRI with targeted biopsy strategies reduce unnecessary biopsies and the detection of clinically insignificant cancers compared with standard biopsy, which may inform biopsy referral practices.

• STHLM3-MRI reported fewer biopsies and fewer clinically insignificant cancers with MRI-directed approaches.
• GOTEBORG-2 found targeted-only biopsy reduced clinically insignificant diagnoses by ~50%.

No explicit authorization or denial triggers provided

The policy sections provided do not list specific authorization or denial triggers; administrative and legal disclaimers note plan-level differences and that the Clinical Policy Bulletin is not a coverage contract.